Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
EpiCept
EpiCept officials describe recent developments
February 14th, 2007
EpiCept officials describe recent developments. This trend article is an immediate alert from NewsRx to identify the most recent news developments at EpiCept. Report 1: EpiCept Corporation (EPCT) announced it entered into a license agreement with DURECT Corporation (DRRX) pursuant to which it has granted DURECT the exclusive, worldwide rights to certain of EpiCept's intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain. Under the terms of the agreement, EpiCept will receive a $1.0 million upfront payment and up to an additional $9.0 million in milestone payments as well as certain...
Source: Medical Patent Law Weekly (2007-02-14)
|
